# Cambridge Cognition awarded contracts totalling £1.4m

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-awarded-contracts-totalling-1.4m/4121000352
- Published: 2021-06-14T07:03:35+01:00
- Author: Giles

**Cambridge Cognition Holdings Plc** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
which develops and markets digital solutions to assess brain health, has today announced
that it has won a series of contracts from a global pharmaceutical company to provide
specialist clinical trial management services.  Under the contracts, the Company
will evaluate a range of digital health and wearable devices and supply the devices
with associated software and services for four clinical trials, which will assess
a drug compound for Central Nervous System (“CNS”) disorders.  Cambridge Cognition
secured the contracts on the strength of its CNS, digital health, clinical trial
and regulatory expertise.

The Company has won four contracts for this work, one in late 2020 and three more
at this time.  The contracts, expected to generate total revenues of c. £1.4m over
two years, are for the supply of software and services as well as the procurement
and provision of third-party hardware, which makes up a considerable portion of 
the total contract value.  As a result of the significant hardware component, the
overall margin on the four contracts is lower than the Company would normally generate
from a software and services led contract.

Pharmaceutical companies are increasingly using digital solutions in virtual or 
part-virtual clinical trials. Cambridge Cognition meets this evolving demand by 
providing a full service offering, from gold-standard assessments and specialist
consultancy, through to secure data repositories and 24/7 trial support.  In delivering
these contracts, Cambridge Cognition will leverage its depth of experience in selecting
and supplying devices for CNS clinical trials, meeting regulatory and good clinical
practice guidance and providing novel endpoints for pharmaceutical clients. 

> **Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:**
> “Cambridge Cognition has earned a reputation for delivering cutting-edge digital
> health solutions with an infrastructure that meets regulatory demands and satisfies
> clients’ needs for clinical trials.  We were approached for this work, the first
> of its kind for the Company, on the strength of this reputation.  The result is
> a new service offering as well as an enhanced relationship with a leading pharmaceutical
> client.”

Share on: